Anticancer Vaccination Program
Cancer
Pre-clinicalActive
Key Facts
About FindImmune
FindImmune is a private, preclinical-stage biotech developing novel immuno-oncology therapies. Its core strategy involves stimulating the immune system for anticancer vaccination and overcoming tumor resistance by modulating the tumor microenvironment, particularly through targeting macrophage checkpoints. As a spin-off from the prestigious Gustave Roussy institute, it benefits from deep scientific expertise and a partnered discovery platform. The company is pre-revenue and aims to advance its lead candidates into the clinic to address significant unmet needs in oncology.
View full company profileTherapeutic Areas
Other Cancer Drugs
| Drug | Company | Phase |
|---|---|---|
| Not Specified (Oncology Focus) | Narwhal Bio | Pre-clinical |
| EDM Platform for Genetic Medicine | Coastar Therapeutics | Pre-clinical |
| CO-1 | Caedo Oncology | Pre-clinical |
| Anti-CD99 monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Anti-HLA class I monoclonal antibody | Caedo Oncology | Discovery/Pre-clinical |
| Triapine® | Nanopharmaceutics | Clinical |
| Ammonium Tetrathiomolybdate | Nanopharmaceutics | Clinical |
| Aza-TdC | Nanopharmaceutics | Clinical |
| Undisclosed Oncology Program(s) | Cell BioEngines | Phase 1 |
| No-alpha IL-2 Mutein | SarcoMed USA | Pre-clinical |
| PMIS Therapeutic | NaturemiRI | Preclinical/Clinical (unspecified) |
| AUM302 (formerly IBL-302) | Inflection Biosciences | Pre-clinical (partnered) |